Sistema de Información Esencial en Terapéutica y Salud

@SIETES7

Última actualización: 14/12/2019
SIETES contiene 92854 citas

 
 
 1 a 20 de 43 siguiente >>
Presentar resultados
Seleccionar todas
1.Enlace a cita original Cita con resumen
Williams CL, Jones ME, Swerdlow AJ, Botting BJ, Davies MC, Jacobs I, Bunch KJ, Murphy MFG, Sutcliffe AG. Risks of ovarian, breast, and corpus uteri cancer in women treated with assisted reproductive technology in Great Britain, 1991-2010: data linkage study including 2.2 million person years of observation. BMJ 2018;362:k2644. [Ref.ID 102818]
2.Enlace a cita original Cita con resumen
Wang R, Kim BV, van Wely M, Johnson NP, Costello MF, Zhang H, Ng EHY, Legro RS, Bhattacharya S, Norman RJ, Mol BWJ. Treatment strategies for women with WHO group II anovulation: systematic review and network meta-analysis. BMJ 2017;356:j138. [Ref.ID 101407]
3.
Anónimo. Drugs for ovulation induction. Med Lett Drugs Ther 2011;53:86-8. [Ref.ID 91381]
4. Cita con resumen
El-Chaar D, Yang Q, Gao J, Bottomley J, Leader A, Wen SW, Walker M. Risk of birth defectes increased in pregnancies conceived by assisted human reproduction. Fertil Steril 2009;92:7. [Ref.ID 87607]
5.Tiene citas relacionadas
Jensen A, Sharif H, Frederiksen K, Kjaer SK. Use of fertility drugs and risk of ovarian cancer: Danish population based cohort study. BMJ 2009;338:580-3. [Ref.ID 85412]
6.Tiene citas relacionadas
Webb PM. Fertility drugs and ovarian cancer. BMJ 2009;338:551-2. [Ref.ID 85409]
7.
Bhattacharya S, Harrild K, Mollison J, Wordsworth S, Tay C, Harrold A, McQueen D, Lyall H, Johnston L, Burrage J, Grossett S, Walton H, Lynch J, Johnstone A, Kini S, Raja A, Templeton A. Clomifene citrate or unstimulated intrauterine insemination compared with expectant management for unexplained infertility: pragmatic randomised controlled trial. BMJ 2008;337:387-90. [Ref.ID 83763]
8. Cita con resumen
Legro RS, Barnhart HX, Schlaff WD, Carr BR, Diamond MP, Carson SA, et al.. Clomiphene, metformin, or both for infertility in the polycystic ovary syndrome. N Engl J Med 2007;356:551-66. [Ref.ID 79218]
10.Tiene citas relacionadas
Al-Inany H, Johnson N. Drugs for anovulatory infertility in polycystic ovary syndrome. BMJ 2006;332:1461-2. [Ref.ID 77388]
11. Cita con resumen
Anónimo. UK doctors reminded about adverse events. Scrip 2006;3157:4. [Ref.ID 76981]
12.Tiene citas relacionadas Cita con resumen
BenEzra D. In-vitro fertilisation and retinoblastoma. Lancet 2003;361:273-4. [Ref.ID 64903]
13. Cita con resumen
De Sloover Kock Y, Ernst ME. Use of metformin in polycystic ovary syndrome. Ann Pharmacother 2001;35:1644-7. [Ref.ID 60974]
15.
Anónimo. Tackling polycistic ovary syndrome. Drug Ther Bull 2001;39:1-5. [Ref.ID 54699]
16.
Gottlieb S. In vitro fertilisation is preferable to fertility drugs. BMJ 2000;321:134. [Ref.ID 51805]
17.Tiene citas relacionadas Cita con resumen
Gleicher N, Oleske DM, Tur-Kaspa I, Vidali A, Karande V. Reducing the risk of high-order multiple pregnancy after ovarian stimulation with gonadotropins. N Engl J Med 2000;343:2-7. [Ref.ID 51719]
18.Tiene citas relacionadas
Fujimoto VY. Ganirelix: a viewpoint. Drugs 2000;59:112-3. [Ref.ID 49382]
19.Tiene citas relacionadas
Strowitzki T. Ganirelix: a viewpoint. Drugs 2000;59:112. [Ref.ID 49381]
20.Tiene citas relacionadas Cita con resumen
Gillies PS, Faulds D, Barman Balfour JA, Perry C M. Ganirelix. Drugs 2000;59:107-11. [Ref.ID 49380]
Seleccionar todas
 
 1 a 20 de 43 siguiente >>